Cytosorbents/$CTSO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytosorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Ticker
$CTSO
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
149
ISIN
US23283X2062
Website
Cytosorbents Metrics
BasicAdvanced
$80M
-
-$0.29
1.05
-
Price and volume
Market cap
$80M
Beta
1.05
52-week high
$1.61
52-week low
$0.70
Average daily volume
103K
Financial strength
Current ratio
2.61
Quick ratio
1.978
Long term debt to equity
182.24
Total debt to equity
185.499
Interest coverage (TTM)
-8.02%
Profitability
EBITDA (TTM)
-14.475
Gross margin (TTM)
69.23%
Net profit margin (TTM)
-45.59%
Operating margin (TTM)
-45.33%
Effective tax rate (TTM)
9.50%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-20.46%
Return on equity (TTM)
-96.25%
Valuation
Price to revenue (TTM)
2.029
Price to book
5.5
Price to tangible book (TTM)
7.38
Price to free cash flow (TTM)
-5.251
Free cash flow yield (TTM)
-19.04%
Free cash flow per share (TTM)
-24.38%
Growth
Revenue change (TTM)
15.37%
Earnings per share change (TTM)
-51.38%
3-year revenue growth (CAGR)
-5.04%
10-year revenue growth (CAGR)
25.03%
3-year earnings per share growth (CAGR)
-24.80%
10-year earnings per share growth (CAGR)
-13.24%
What the Analysts think about Cytosorbents
Analyst ratings (Buy, Hold, Sell) for Cytosorbents stock.
Cytosorbents Financial Performance
Revenues and expenses
Cytosorbents Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytosorbents stock?
Cytosorbents (CTSO) has a market cap of $80M as of July 01, 2025.
What is the P/E ratio for Cytosorbents stock?
The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of July 01, 2025.
Does Cytosorbents stock pay dividends?
No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Cytosorbents dividend payment date?
Cytosorbents (CTSO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytosorbents?
Cytosorbents (CTSO) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.